Second, AD biomarkers of amyloid β and tau were not available; thus, this study could not provide direct evidence on whether baseline spatial navigation could help identify the SCD subjects with positive AD biomarkers from the whole SCD entity. This evidence concerns the gene MAPT and Alzheimer disease.